Catalyst · readout
REDEFINE 1 topline readout anticipated in 2025.
Expected: Jan 1, 2025 – Jun 30, 2025
Catalyst details
- Type
- readout
- Status
- pending
- Date precision
- window
- Confidence
- company guidance
- Asset
- Cagrisema
- Company
- Novo Nordisk
Dependencies
- trial-04
Source wording
“REDEFINE 1 topline readout anticipated in 2025.”
Sources
- registryprimary record
REDEFINE 1: Cagrisema for weight management in adults with overweight or obesity
Novo Nordisk A/S · ClinicalTrials.gov · Jul 13, 2023 · NCT05929066